Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Vepoloxamer in Chronic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 through 74~* Duration of documented heart failure \>3 months~* On stable concomitant medication regimen ≥4 weeks~* Left ventricular ejection fraction ≤35%~* Systolic blood pressure ≥90 mmHg~Exclusion Criteria:~* Severe valvular stenosis or primary valvular regurgitation as the cause of heart failure~* History of myocardial infarction, coronary artery bypass graft surgery, or percutaneous intervention within the prior 3 months~* Estimated glomerular filtration rate ≤45 mL/min/1.73 m2~* Acutely decompensated heart failure within 1 month prior to the screening visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Vepoloxamer - Low dose (Type: EXPERIMENTAL): Vepoloxamer injection administered intravenously 225 mg/kg over 3 hours
- Vepoloxamer - High dose (Type: EXPERIMENTAL): Vepoloxamer injection administered intravenously 450 mg/kg over 3 hours
- 5% dextrose in water (D5W) (Type: PLACEBO_COMPARATOR): D5W administered intravenously over 3 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).